Compare Sun Pharma with Orchid Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ORCHID PHARMA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ORCHID PHARMA 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ORCHID PHARMA SUN PHARMA/
ORCHID PHARMA
 
P/E (TTM) x 84.7 -129.0 - View Chart
P/BV x 3.6 37.0 9.8% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 SUN PHARMA   ORCHID PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-20
ORCHID PHARMA
Sep-13
SUN PHARMA/
ORCHID PHARMA
5-Yr Chart
Click to enlarge
High Rs484194 249.5%   
Low Rs31535 900.6%   
Sales per share (Unadj.) Rs136.9276.5 49.5%  
Earnings per share (Unadj.) Rs17.5-79.2 -22.0%  
Cash flow per share (Unadj.) Rs26.0-43.5 -59.9%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs188.753.9 349.8%  
Shares outstanding (eoy) m2,399.2670.45 3,405.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.90.4 705.1%   
Avg P/E ratio x22.9-1.4 -1,584.3%  
P/CF ratio (eoy) x15.4-2.6 -583.2%  
Price / Book Value ratio x2.12.1 99.8%  
Dividend payout %22.90-   
Avg Mkt Cap Rs m958,8648,067 11,887.0%   
No. of employees `00017.82.8 634.3%   
Total wages/salary Rs m63,6242,527 2,517.7%   
Avg. sales/employee Rs Th18,490.66,956.1 265.8%   
Avg. wages/employee Rs Th3,582.6902.5 397.0%   
Avg. net profit/employee Rs Th2,357.6-1,993.0 -118.3%   
INCOME DATA
Net Sales Rs m328,37519,477 1,686.0%  
Other income Rs m6,360407 1,561.8%   
Total revenues Rs m334,73519,884 1,683.4%   
Gross profit Rs m69,8981,103 6,339.3%  
Depreciation Rs m20,5282,519 814.9%   
Interest Rs m3,0275,227 57.9%   
Profit before tax Rs m52,702-6,236 -845.1%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,606511 -510.1%   
Tax Rs m8,228-125 -6,571.9%   
Profit after tax Rs m41,868-5,580 -750.3%  
Gross profit margin %21.35.7 376.0%  
Effective tax rate %15.62.0 777.6%   
Net profit margin %12.8-28.7 -44.5%  
BALANCE SHEET DATA
Current assets Rs m316,54211,014 2,873.9%   
Current liabilities Rs m157,06432,060 489.9%   
Net working cap to sales %48.6-108.1 -44.9%  
Current ratio x2.00.3 586.6%  
Inventory Days Days8895 92.3%  
Debtors Days Days10534 312.1%  
Net fixed assets Rs m243,10229,440 825.8%   
Share capital Rs m2,399705 340.6%   
"Free" reserves Rs m450,2452,043 22,042.7%   
Net worth Rs m452,6453,800 11,912.0%   
Long term debt Rs m20,2899,018 225.0%   
Total assets Rs m682,52546,510 1,467.5%  
Interest coverage x18.4-0.2 -9,532.4%   
Debt to equity ratio x02.4 1.9%  
Sales to assets ratio x0.50.4 114.9%   
Return on assets %6.6-0.8 -865.5%  
Return on equity %9.2-146.9 -6.3%  
Return on capital %11.2-3.7 -300.8%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m74,2197,513 987.8%   
Fx outflow Rs m27,9645,649 495.0%   
Net fx Rs m46,2551,865 2,480.8%   
CASH FLOW
From Operations Rs m65,5481,682 3,897.7%  
From Investments Rs m-25,888-9,860 262.5%  
From Financial Activity Rs m-57,1516,644 -860.2%  
Net Cashflow Rs m-13,857-1,535 902.7%  

Share Holding

Indian Promoters % 63.7 32.3 197.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 4.6 111.5%  
FIIs % 23.0 3.3 697.0%  
ADR/GDR % 0.0 4.6 -  
Free float % 8.3 55.3 15.0%  
Shareholders   133,026 84,811 156.8%  
Pledged promoter(s) holding % 0.5 54.9 1.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   WOCKHARDT  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  BIOCON   FULFORD INDIA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


May 7, 2021 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS